Your browser doesn't support javascript.
loading
Buccal lidocaine mucoadhesive patches for pediatrics' teething pain: overcoming possible hazards of oral gels.
Bebawy, George; Sokar, Magda Samir; Abdallah, Ossama Y.
Afiliação
  • Bebawy G; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Sokar MS; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Abdallah OY; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Pharm Dev Technol ; 29(8): 805-813, 2024 Oct.
Article em En | MEDLINE | ID: mdl-39166264
ABSTRACT

OBJECTIVES:

The utilization of pharmaceutical products in pediatric medicine, while established for use in adults, often presents uncertainties due to differences in application for children. The FDA discourages the use of local anesthetic gels, notably lidocaine, for teething pain in pediatrics due to concerns regarding potential adverse effects if inadvertently swallowed excessively. Therefore, significant attention is being directed towards modifying available marketed products to make them suitable for pediatric use. Here, we introduce mucoadhesive patches that not only have an adjusted dose of lidocaine but also feature a controlled release profile to manage teething pain with prolonged effect. This design helps to prevent issues related to gel liquefaction and swallowing, thereby reducing the potential hazardous side effects of lidocaine in the pediatric population.

METHODS:

The study involved the development of controlled-release lidocaine HCl-loaded pellets forming a matrix for inclusion in mucoadhesive patches. Characterization was performed to ensure prolonged drug release, particularly during overnight use, aiming to improve pediatric patient compliance and enable precise dosing. KEY

FINDINGS:

The mucoadhesive patches exhibited sustained lidocaine release lasting 24 h, potentially offering overnight relief suitable for pediatric application. The analysis of lidocaine content revealed that the developed patches maintained stable levels compared to doses obtained from commercially available oral gels. This finding implies effective pain control without the need for frequent reapplications, alongside controlled doses that decrease the likelihood of side effects.

CONCLUSION:

The formulated medicated patches demonstrated consistent lidocaine content, effectively controlled drug release, and consequently, reduced the likelihood of undesired side effects when compared to oral gel administration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preparações de Ação Retardada / Géis / Anestésicos Locais / Lidocaína / Mucosa Bucal Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preparações de Ação Retardada / Géis / Anestésicos Locais / Lidocaína / Mucosa Bucal Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article